All the top Biotech & Pharma news in one daily newsletter.

What to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

Looking to reach an audience of 700+ biotech and pharma professionals? Let’s chat. 👍

THE GOOD
Approvals & Labels

Ascendis Pharma’s rare endocrine disorder med lands FDA approval
Peptide, hormone replacement therapy, hypoparathyroidism - Read more

Sandoz’s Eylea biosimilar (Regeneron) nabs FDA approval
Recombinant fusion protein, biosimilar, wet age-related macular degeneration - Read more

scPharmaceuticals gains FDA label expansion for heart failure med
Small molecule, heart failure, congestion due to fluid overload - Read more 

THE GOOD
Business Development

Guangzhou Lupeng Pharmaceutical, Hansoh Pharmaceutical licensing arrangement within China
Small molecule, autoimmune - Read more

THE GOOD
Clinical Trials

Pfizer reels in Ph3 win for RSV vaccine in immunocompromised individuals, gunning for label expansion
Vaccine, respiratory syncytial virus (RSV) - Read more

Locus Biosciences ELIMINATES some doubt about their bacteriophage med with Ph2 (part 1) positive results
CRISPR-Cas3, engineered bacteriophage therapy, uncomplicated urinary tract infection, antimicrobial-resistant, multi-drug-resistant - Read more

Tonix Pharmaceuticals presents RESILIENT-ly positive Ph3 data for their fibromyalgia med
Small molecule, fibromyalgia, nociplastic syndrome - Read more

PRESENTED BY THE UBC SCHOOL OF BIOMEDICAL ENGINEERING
Today’s Ideas. Tomorrow’s Solutions.

Driving innovation in Canada’s biotech and life sciences sectors requires a complex and specialized skill set. The UBC Micro-certificate in Innovation Leadership: Medical & Bio-Innovations equips professionals with the practical, legal, and strategic skills needed to translate technological and scientific innovations into improved patient outcomes and healthcare impacts.

Learn how to identify and address unmet patient needs while implementing intellectual property strategies that protect and leverage healthcare innovations. Gain relevant, in-demand skills from a diverse panel of industry experts, which you can apply immediately in your professional role or organization.

Course enrolment is now open. Learn more and register today!

⬇️ The Good News (Cont’d) ⬇️

THE GOOD
Fundraises

Halda Therapeutics $126M Series B
Small molecule, prostate cancer - Read more

Tenax Therapeutics closes $100M private placement
Small molecule, pulmonary hypertension, heart failure - Read more

MeiraGTx $50M ordinary share offering, led by Sanofi with $30M investment
Gene therapy, X-Linked Retinitis Pigmentosa, Parkinson’s disease - Read more

scPharmaceuticals proposed public offering
Small molecule, heart failure, congestion due to fluid overload - Read more

THE GOOD
Investments

Despite Biosecure murmurs, Legend Biotech continues with cell therapy factory build
CAR-T cell therapy, multiple myeloma, cancer - Read more [Paywall]

THE GOOD
Lawsuits

J&J’s talc saga may be ending, as 75% of claimants vote in favor of a proposed $6.5B settlement
Talc, mineral, ovarian cancer - Read more

THE GOOD
Mergers & Acquisitions

Crown Laboratories buys Revance Therapeutics for $924M, competing with botox rival AbbVie 
Recombinant protein, neurotoxin, glabellar lines, cervical dystonia - Read more

Stryker strykes deal to acquire care.ai
Medical device, remote patient monitoring, smart hospital system - Read more

THE GOOD
Partnerships

Absci, Memorial Sloan Kettering Cancer Center (MSK) gen-AI driven oncology drug discovery pact
Generative AI, drug discovery & development, cancer - Read more

THE GOOD
Politics & Policy

Democrats call on administration to finalize rules regarding “march-in rights” to combat high drug prices
Drug pricing, march-in rights, drug patent - Read more

THE GOOD
Product Launches

Microsoft, Paige unveil 2nd gen image-based cancer diagnosis AI model
AI, cancer diagnosis - Read more 

THE GOOD
Research

Largest protein so far (aptly named PKZILLA) discovered in marine algae
Protein discovery, marine algae, toxin - Read more

THE GOOD
Strategic Plans

Despite initial rejection, Novo Nordisk pushes ahead with once-weekly insulin/semaglutide combination bid
GLP-1, insulin, type 2 diabetes - Read more

ENJOYING THESE NEWSLETTERS?
Support TLDR Biotech.

It’s a lot of work to put together a daily newsletter, and it’s currently just me writing these things (+ one part-time contractor - no fancy editing team).

If you’re getting value out of these daily compilations, please consider a paid subscription (only $5/month) to support my continued work on this project.

THE BAD
Approvals & Labels

Humacyte’s BLA decision delayed, FDA requires additional time
Bioengineered human tissue, acellular tissue engineered vessel, arterial replacement and repair - Read more

THE BAD
Clinical Trals

Actinogen Medical depression hopeful misses Ph2 primary endpoint
Small molecule, cognitive dysfunction, major depressive disorder - Read more

THE BAD
Layoffs

FibroGen to lay off 127 staffers at San Francisco location
Monoclonal antibody, small molecule, cancer, chemotherapy-induced anemia - Read more

THE BAD
Politics & Policy

Biopharma industry keeping tabs on growing anti-China legislation, mentioned in multiple SEC filings
Biosecure act - Read more [Paywall]

THE BAD
Strategic Plans

As BiVictriX Therapeutics’ war chest dwindles, they decide their fortunes favour going private to bring their asset to clinical trials
Antibody-drug conjugate, leukemia, cancer - Read more

THE UGLY
No Ugly News Today!

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

Last thing - if you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here.